Zobrazeno 1 - 10
of 113
pro vyhledávání: '"William L Macias"'
Autor:
Richard J. Nowak, Ari Breiner, Vera Bril, Jeffrey A. Allen, Shaida Khan, Todd Levine, Daniel H. Jacobs, Gregory Sahagian, Zaeem A. Siddiqi, Jing Xu, William L. Macias, Michael Benatar, ASCEND MG Study Group
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 1, Pp 194-206 (2024)
Abstract Objectives To assess the safety, tolerability, and key pharmacodynamic effects of subcutaneous batoclimab, a fully human anti‐neonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia gravis and anti‐acetylcholine
Externí odkaz:
https://doaj.org/article/88f6f869acee42ffae3f50c106820b47
Autor:
Iain B. McInnes, Nicole L. Byers, Richard E. Higgs, Jonathan Lee, William L. Macias, Songqing Na, Robert A. Ortmann, Guilherme Rocha, Terence P. Rooney, Thomas Wehrman, Xin Zhang, Steven H. Zuckerman, Peter C. Taylor
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. Methods Peripheral blood mononuclear cells from healthy dono
Externí odkaz:
https://doaj.org/article/9199674c675b4aa38a99899ed7156b79
Autor:
Mark C. Genovese, William L. Macias, Edward C. Keystone, Doug E. Schlichting, Charles Peterfy, Monica E. Luchi, Paul Emery, Julie C DiCarlo, Scott D. Beattie, Peter C. Taylor
Publikováno v:
The Journal of Rheumatology. 46:887-895
Objective.Magnetic resonance imaging (MRI) was used in a phase IIb study of baricitinib in patients with RA to support dose selection for the phase III program.Methods.Three hundred one patients with active RA who were taking stable methotrexate were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125a67db6ba87e7173daea506f8962a3
https://doi.org/10.3899/jrheum.171469
https://doi.org/10.3899/jrheum.171469
Autor:
William L. Macias, David L. Hyslop, Jennifer Riddle Camp, Kevin L. Winthrop, L. Chen, Josef S Smolen, Tsutomu Takeuchi, Mark C. Genovese, T. Ishii, C. Dickson, Terence Rooney, Tracy Cardillo
Publikováno v:
The Journal of Rheumatology. 46:7-18
Objective.Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib’s safety profile through 288 weeks (up to September 1, 2016)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4612321f8e52d06df570fd6eac1d89
https://doi.org/10.3899/jrheum.171361
https://doi.org/10.3899/jrheum.171361
Autor:
Rena Klar, Terence Rooney, Mark C. Genovese, William L. Macias, Josef S Smolen, Boulos Haraoui, Inmaculada de la Torre, Li Xie, Ana Pinto-Correia, Pedro Lopez-Romero, Susan Otawa, Tsutomu Takeuchi, Zhanguo Li
Publikováno v:
Annals of the Rheumatic Diseases. 78:171-178
ObjectivesThis study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day.MethodsPatients who completed a baricitinib phase 3 study could enter a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6b2e3f2b845caf53c367ba2d2d5fa59
https://doi.org/10.1136/annrheumdis-2018-213271
https://doi.org/10.1136/annrheumdis-2018-213271
Autor:
Frank C. Brosius, Ravindra L. Mehta, Fabio P. Nunes, William L. Macias, Katherine R. Tuttle, Sharon G. Adler, Jonathan Janes, Kevin L. Duffin, James A. Tumlin, Maria E Silk, Joseph V. Haas, Jiajun Liu, Matthias Kretzler, Yoshiya Tanaka, Masakazu Haneda, Tracy Cardillo
Publikováno v:
Nephrology Dialysis Transplantation
Background Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa6a61356c723b0139d49362d65a11c0
https://doi.org/10.1093/ndt/gfx377
https://doi.org/10.1093/ndt/gfx377
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Autor:
Juan Sanchez Burson, Cynthia E. Kartman, Hans-Peter Tony, Mark C. Genovese, William L. Macias, Josef S Smolen, Li Xie, Joel M. Kremer, Douglas E Schlichting, Carlos Pantojas, Tara Carmack, Terence Rooney
Publikováno v:
Rheumatology (Oxford, England)
Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. Methods RA-BEACON patients (pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec498ce49b90b82ab9928b1d42cfc9bd
https://doi.org/10.1093/rheumatology/kex489
https://doi.org/10.1093/rheumatology/kex489
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:804-813
Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2. It demonstrated dose-dependent efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) in a phase IIb study up to 24 weeks. Population pharmacokinetic/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90159b3bdaa8137886613eb591128b30
https://doi.org/10.1002/psp4.12251
https://doi.org/10.1002/psp4.12251
Autor:
Peter C. Taylor, William L. Macias, Edward C. Keystone, Liliana del Carmen Morales, Vipin Arora, Jaime Reyes Gonzaga, Stephanie de Bono, Michael E. Weinblatt, Scott Beattie, Carol L. Gaich, Terence Rooney, Désirée van der Heijde, K. Emoto, T. Ishii, Yoshiya Tanaka, Sergey Yakushin, Douglas E Schlichting
Publikováno v:
New England Journal of Medicine, 376(7), 652-662
Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c0a8db0360c84bae216db0f3e4c54a4
https://doi.org/10.1056/nejmoa1608345
https://doi.org/10.1056/nejmoa1608345
Autor:
Xiang Zhang, Douglas E Schlichting, William L. Macias, M.A. Menter, D. Disch, Jonathan Janes, M. Raman, Carol L. Gaich, Kim A. Papp
Publikováno v:
British Journal of Dermatology. 174:1266-1276
SummaryBackground Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process. Objectives To evaluate the safety and efficacy of baricitinib, an oral Janus kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973a7c5547269fb77a32e48dee83025f
https://doi.org/10.1111/bjd.14403
https://doi.org/10.1111/bjd.14403